318 related articles for article (PubMed ID: 31692172)
1. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
2. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
3. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.
Okazaki S; Shintani S; Hirata Y; Suina K; Semba T; Yamasaki J; Umene K; Ishikawa M; Saya H; Nagano O
Oncotarget; 2018 Sep; 9(73):33832-33843. PubMed ID: 30333913
[TBL] [Abstract][Full Text] [Related]
5. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
6. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
7. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
[TBL] [Abstract][Full Text] [Related]
8. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose.
Joly JH; Delfarah A; Phung PS; Parrish S; Graham NA
J Biol Chem; 2020 Jan; 295(5):1350-1365. PubMed ID: 31914417
[TBL] [Abstract][Full Text] [Related]
9. Ambidextrous Approach To Disrupt Redox Balance in Tumor Cells with Increased ROS Production and Decreased GSH Synthesis for Cancer Therapy.
Kou L; Sun R; Xiao S; Zheng Y; Chen Z; Cai A; Zheng H; Yao Q; Ganapathy V; Chen R
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26722-26730. PubMed ID: 31276364
[TBL] [Abstract][Full Text] [Related]
10. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
11. Mn Inhibits GSH Synthesis via Downregulation of Neuronal EAAC1 and Astrocytic xCT to Cause Oxidative Damage in the Striatum of Mice.
Yang X; Yang H; Wu F; Qi Z; Li J; Xu B; Liu W; Xu Z; Deng Y
Oxid Med Cell Longev; 2018; 2018():4235695. PubMed ID: 30228854
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
14. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
Sleire L; Skeie BS; Netland IA; Førde HE; Dodoo E; Selheim F; Leiss L; Heggdal JI; Pedersen PH; Wang J; Enger PØ
Oncogene; 2015 Dec; 34(49):5951-9. PubMed ID: 25798841
[TBL] [Abstract][Full Text] [Related]
15. Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Ju HQ; Lu YX; Chen DL; Tian T; Mo HY; Wei XL; Liao JW; Wang F; Zeng ZL; Pelicano H; Aguilar M; Jia WH; Xu RH
Theranostics; 2016; 6(8):1160-75. PubMed ID: 27279909
[TBL] [Abstract][Full Text] [Related]
16. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death.
Banjac A; Perisic T; Sato H; Seiler A; Bannai S; Weiss N; Kölle P; Tschoep K; Issels RD; Daniel PT; Conrad M; Bornkamm GW
Oncogene; 2008 Mar; 27(11):1618-28. PubMed ID: 17828297
[TBL] [Abstract][Full Text] [Related]
17. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
Tsuchihashi K; Okazaki S; Ohmura M; Ishikawa M; Sampetrean O; Onishi N; Wakimoto H; Yoshikawa M; Seishima R; Iwasaki Y; Morikawa T; Abe S; Takao A; Shimizu M; Masuko T; Nagane M; Furnari FB; Akiyama T; Suematsu M; Baba E; Akashi K; Saya H; Nagano O
Cancer Res; 2016 May; 76(10):2954-63. PubMed ID: 26980765
[TBL] [Abstract][Full Text] [Related]
18. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Garcia CG; Kahn SA; Geraldo LHM; Romano I; Domith I; Silva DCLE; Dos Santos Assunção F; Ferreira MJ; Portugal CC; de Souza JM; Romão LF; Netto ADP; Lima FRS; Cossenza M
Mol Neurobiol; 2018 Aug; 55(8):6816-6833. PubMed ID: 29349577
[TBL] [Abstract][Full Text] [Related]
20. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
